Evidence map›Paper›PMID 26207246›Full record

ArticleAnnals of translational medicine2015

Chromogranin A as a predictor of radiological disease progression in neuroendocrine tumours.

Roberta Elisa Rossi, Jorge Garcia-Hernandez, Tim Meyer, Christina Thirlwell, Jennifer Watkins, Nicholas Guy Martin, Martyn Evan Caplin, Christos Toumpanakis

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of translational medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Limited role of Chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2019
    Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 2 countries.

Roberta Elisa Rossi1 Neuroendocrine Tumour Unit, Centre of Gastroenterology, Royal Free Hospital, London, UK ; 2 Gastroenterology and Endoscopy Unit Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico and Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy ; 3 Cancer Institute, University College London, London, UK ; 4 Department of Histopathology, 5 Department of Clinical Biochemistry, Royal Free Hospital, London, UK.
Jorge Garcia-Hernandez1 Neuroendocrine Tumour Unit, Centre of Gastroenterology, Royal Free Hospital, London, UK ; 2 Gastroenterology and Endoscopy Unit Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico and Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy ; 3 Cancer Institute, University College London, London, UK ; 4 Department of Histopathology, 5 Department of Clinical Biochemistry, Royal Free Hospital, London, UK.
Tim Meyer1 Neuroendocrine Tumour Unit, Centre of Gastroenterology, Royal Free Hospital, London, UK ; 2 Gastroenterology and Endoscopy Unit Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico and Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy ; 3 Cancer Institute, University College London, London, UK ; 4 Department of Histopathology, 5 Department of Clinical Biochemistry, Royal Free Hospital, London, UK.
Christina Thirlwell1 Neuroendocrine Tumour Unit, Centre of Gastroenterology, Royal Free Hospital, London, UK ; 2 Gastroenterology and Endoscopy Unit Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico and Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy ; 3 Cancer Institute, University College London, London, UK ; 4 Department of Histopathology, 5 Department of Clinical Biochemistry, Royal Free Hospital, London, UK.
Jennifer Watkins1 Neuroendocrine Tumour Unit, Centre of Gastroenterology, Royal Free Hospital, London, UK ; 2 Gastroenterology and Endoscopy Unit Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico and Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy ; 3 Cancer Institute, University College London, London, UK ; 4 Department of Histopathology, 5 Department of Clinical Biochemistry, Royal Free Hospital, London, UK.
Nicholas Guy Martin1 Neuroendocrine Tumour Unit, Centre of Gastroenterology, Royal Free Hospital, London, UK ; 2 Gastroenterology and Endoscopy Unit Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico and Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy ; 3 Cancer Institute, University College London, London, UK ; 4 Department of Histopathology, 5 Department of Clinical Biochemistry, Royal Free Hospital, London, UK.
Martyn Evan Caplin1 Neuroendocrine Tumour Unit, Centre of Gastroenterology, Royal Free Hospital, London, UK ; 2 Gastroenterology and Endoscopy Unit Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico and Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy ; 3 Cancer Institute, University College London, London, UK ; 4 Department of Histopathology, 5 Department of Clinical Biochemistry, Royal Free Hospital, London, UK.
Christos Toumpanakis1 Neuroendocrine Tumour Unit, Centre of Gastroenterology, Royal Free Hospital, London, UK ; 2 Gastroenterology and Endoscopy Unit Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico and Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy ; 3 Cancer Institute, University College London, London, UK ; 4 Department of Histopathology, 5 Department of Clinical Biochemistry, Royal Free Hospital, London, UK.
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChromogranin A (CgA) is the best established neuroendocrine biomarker. This study was aimed at investigating the prognostic value of CgA as a predictor of radiological disease progression in neuroendocrine tumour (NET) patients.

methodsPatients with metastatic NETs and evidence of radiological progression (RP) according to RECIST 1.1 were identified from a NET database. Plasma CgA levels were measured 6 and 12 months before RP and at the event of RP. CgA was measured with the Supra-regional-Assay-Service radioimmunoassay (Hammersmith Hospital).

resultsA total of 152 patients were evaluated including 91 midgut NETs and 61 pancreatic NETs (PNETs). Of these, 56 were G1 NETs, 65 G2, 10 G3, 21 of unknown histology. For all NETs, there was a positive trend in terms of increase of CgA values 6 months prior to RP compared to 12 months before RP. Subgroup analysis at first episode of RP showed that for PNETs there was evidence of a difference in the median CgA levels. CgA 6 months before RP was 100 pmol/L [interquartile 1 (Q1) =53 and Q3 =286.25 pmol/L) and 12 months before was 52 pmol/L (Q1 =36.25 and Q3 =128 pmol/L), W=52, P=0.48. This observation was not confirmed in midgut NETs, where median CgA 6 months before RP was 389.5 pmol/L (Q1 =131.5 and Q3 =791.5 pmol/L) and 12 months before was 319 pmol/L (Q1 =158 and Q3 =753 pmol/L), W=191, P=0.39]. Low grade tumours (G1) had a median CgA value at 6 months significantly higher than at 12 months [181 (Q1 =56.25, Q3 =624) vs. 149.5 (Q1 =44, Q3 =247.25) pmol/L, W=70, P=0.48].

conclusionsCgA seems to have predictive value 6 months prior to RP for PNETs and G1 tumours. Further prospective analyses are needed to enable more definitive conclusions.

Indexed as

Chromogranin A (CgA)neuroendocrine tumour (NET)prognosisradiological disease progressiontumour markers

Identifiers

PMID26207246
PMCPMC4481369
OpenAlexW310039941

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.